基于Cortellis数据库的肿瘤免疫治疗药物研发态势分析
|
摘要
本研究基于Cortellis数据库,采用定量分析与定性分析相结合的方法,从研发现状、研发国家/地区、研发机构、适应证、作用靶点、重磅药物、交易合作类型等多角度研究肿瘤免疫治疗药物的研发态势。有2 507家机构开展研究,全球肿瘤免疫治疗药物共有4 097个,上市药物有214个,其中2016年销售额超过10亿美元的重磅药物有28个。美国是开展肿瘤免疫治疗研究最多的国家,主要研发机构是欧美发达国家的科研机构和大型制药企业。肿瘤免疫治疗药物的适应证以各种实体瘤为主,作用靶点主要集中在各种抑制剂和调节剂。肿瘤免疫治疗药物相关的交易合作以药物开发及商业合作授权、早期研究与开发2种类型占据主导地位。肿瘤免疫治疗药物发展势头迅猛、上升潜力大、市场前景看好。
This paper discussed the development situation of tumor immunotherapy drugs in multi-perspective views from research status,countries/regions,institutions,indications,targets,blockbuster drugs,and types of transaction cooperation based on the Cortellis database,with the combination of quantitative and qualitative analysis.The study found that there were 2 507 institutions and 4 097 tumor immunotherapy drugs all over the world,214 drugs were on the market including 28 blockbuster drugs which had more than 1 billion dollars in 2016 sales. USA is the country which has carried out the most tumor immunotherapy research. The main R&D institutions were scientific research institutions and large-scale pharmaceutical companies in the European and American developed countries. The indications for tumor immunotherapy drugs were mainly solid tumors,and their targets were mostly concentrated on inhibitors and modulators. Transaction types of tumor immunotherapy drugs were dominated by drug development and commercial license,and early research and development. Tumor immunotherapy drugs has developed rapidly,with great growth potential and promising market prospects.
This paper discussed the development situation of tumor immunotherapy drugs in multi-perspective views from research status,countries/regions,institutions,indications,targets,blockbuster drugs,and types of transaction cooperation based on the Cortellis database,with the combination of quantitative and qualitative analysis.The study found that there were 2 507 institutions and 4 097 tumor immunotherapy drugs all over the world,214 drugs were on the market including 28 blockbuster drugs which had more than 1 billion dollars in 2016 sales. USA is the country which has carried out the most tumor immunotherapy research. The main R&D institutions were scientific research institutions and large-scale pharmaceutical companies in the European and American developed countries. The indications for tumor immunotherapy drugs were mainly solid tumors,and their targets were mostly concentrated on inhibitors and modulators. Transaction types of tumor immunotherapy drugs were dominated by drug development and commercial license,and early research and development. Tumor immunotherapy drugs has developed rapidly,with great growth potential and promising market prospects.
引文
[1] ZHANG T,CHEN J,JIA X. Identification of the key fields and their key technical points of oncology by patent analysis[J]. Plos One,2015,10:e014357311.
[2] SIEGEL RL,MILLER KD,JEMAL A. Cancer statistics,2017[J]. CA-A Cancer J Clinic,2017,67(1):7-30.
[3]张婷,陈娟,程才,等.基于文献计量学的肿瘤领域发展态势研究[J].中国肿瘤,2015,24(11):949-956.
[4] BALKO JM,SOSMAN JA. A critical need for better cancer immunotherapy models:are organotypic tumor spheroid cultures the answer?[J]. Cancer Discov,2018,8(2):143-145.
[5]黄波.肿瘤免疫肿瘤免疫:肿瘤治疗的新希望[J].科技导报,2016,34(20):18-24.
[6] ROUTY B,LE CHATELIER E,DEROSA L,et al. Gut micro-biome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science,2018,359(6371):91.
[7] BOXBERG M,STEIGER K,LENZE U,et al. PD-L1 and PD-1and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue-prognostic implications and rationale for immunotherapy[J]. Oncoimmunol,2018,7:e13893663.
[8]高云华,徐守军,刁天喜.抗体药物研究进展[J].中国新药杂志,2014,23(20):2414-2417.
[9] RIZVI NA,GETTINGER SN,HORN L,et al. Nivolumab(antiPD-1,BMS-936558,ONO-4538)in patients with advanced nonsmall cell lung cancer(NSCLC):survival and clinical activity by subgroup analysis[J]. J Thoracic Oncol,2014,93(9):152.
[10] CARBOGNIN L,PILOTTO S,MILELLA M,et al. Differential activity of nivolumab,pembrolizumab and MPDL3280A according to the tumor expression of programmed death-Ligand-1(PD-L1):sensitivity analysis of trials in melanoma,lung and genitourinary cancers[J]. Plos One,2015,10:e01301426.
[11]叶因涛,王晨,孙蓓. PD-1/PD-L1抑制剂在肿瘤免疫治疗中的研究进展[J].中国肿瘤临床,2015,42(24):1178-1182.
[12]王莉,张志叶. PD-1抑制剂新药nivolumab[J].中国新药杂志,2016,25(9):961-963.
[13] ALEGRE-DEL EJ,NOGAL FB,BRICENO-CASADO P. Nivolumab and ipilimumab in advanced melanoma[J]. N Engl J Med,2017,377(25):2503.
[14] O'NEIL BH,WALLMARK JM,LORENTE D,et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma[J]. Plos One,2017,12:e018984812.
[15] GARON EB,RIZVI NA,HUI R,et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med,2015,372(21):2018-2028.
[16]毛开云,范月蕾,王跃,等.间充质干细胞治疗产品开发现状与趋势[J].中国生物工程杂志,2017,37(10):126-134.
[17]从俊杰,宿央央,霍春芳,等. PD-1/PD-L1抗体的专利分析[J].今日药学,2017,27(6):420-424,429.
[18]刘玲玲,王盈,吴霖萍,等.全球药品研发进展(2016. 09~2016. 12)[J].中国医药工业杂志,2017,48(3):453-467.
[19]阮水良,韩晨阳,官俏兵.来那度胺抑制PD1/PD-L1信号调节淋巴细胞对HepG2的免疫杀伤作用[J].中国现代应用药学,2018,35(10):1457-1461.
[2] SIEGEL RL,MILLER KD,JEMAL A. Cancer statistics,2017[J]. CA-A Cancer J Clinic,2017,67(1):7-30.
[3]张婷,陈娟,程才,等.基于文献计量学的肿瘤领域发展态势研究[J].中国肿瘤,2015,24(11):949-956.
[4] BALKO JM,SOSMAN JA. A critical need for better cancer immunotherapy models:are organotypic tumor spheroid cultures the answer?[J]. Cancer Discov,2018,8(2):143-145.
[5]黄波.肿瘤免疫肿瘤免疫:肿瘤治疗的新希望[J].科技导报,2016,34(20):18-24.
[6] ROUTY B,LE CHATELIER E,DEROSA L,et al. Gut micro-biome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science,2018,359(6371):91.
[7] BOXBERG M,STEIGER K,LENZE U,et al. PD-L1 and PD-1and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue-prognostic implications and rationale for immunotherapy[J]. Oncoimmunol,2018,7:e13893663.
[8]高云华,徐守军,刁天喜.抗体药物研究进展[J].中国新药杂志,2014,23(20):2414-2417.
[9] RIZVI NA,GETTINGER SN,HORN L,et al. Nivolumab(antiPD-1,BMS-936558,ONO-4538)in patients with advanced nonsmall cell lung cancer(NSCLC):survival and clinical activity by subgroup analysis[J]. J Thoracic Oncol,2014,93(9):152.
[10] CARBOGNIN L,PILOTTO S,MILELLA M,et al. Differential activity of nivolumab,pembrolizumab and MPDL3280A according to the tumor expression of programmed death-Ligand-1(PD-L1):sensitivity analysis of trials in melanoma,lung and genitourinary cancers[J]. Plos One,2015,10:e01301426.
[11]叶因涛,王晨,孙蓓. PD-1/PD-L1抑制剂在肿瘤免疫治疗中的研究进展[J].中国肿瘤临床,2015,42(24):1178-1182.
[12]王莉,张志叶. PD-1抑制剂新药nivolumab[J].中国新药杂志,2016,25(9):961-963.
[13] ALEGRE-DEL EJ,NOGAL FB,BRICENO-CASADO P. Nivolumab and ipilimumab in advanced melanoma[J]. N Engl J Med,2017,377(25):2503.
[14] O'NEIL BH,WALLMARK JM,LORENTE D,et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma[J]. Plos One,2017,12:e018984812.
[15] GARON EB,RIZVI NA,HUI R,et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med,2015,372(21):2018-2028.
[16]毛开云,范月蕾,王跃,等.间充质干细胞治疗产品开发现状与趋势[J].中国生物工程杂志,2017,37(10):126-134.
[17]从俊杰,宿央央,霍春芳,等. PD-1/PD-L1抗体的专利分析[J].今日药学,2017,27(6):420-424,429.
[18]刘玲玲,王盈,吴霖萍,等.全球药品研发进展(2016. 09~2016. 12)[J].中国医药工业杂志,2017,48(3):453-467.
[19]阮水良,韩晨阳,官俏兵.来那度胺抑制PD1/PD-L1信号调节淋巴细胞对HepG2的免疫杀伤作用[J].中国现代应用药学,2018,35(10):1457-1461.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |